[HTML][HTML] Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA
B Hahn, M Hull, C Blauer-Peterson, AR Buikema… - Respiratory …, 2018 - Elsevier
Background Improved outcomes have been reported for patients with chronic obstructive
pulmonary disease (COPD) receiving combination long-acting muscarinic antagonist/long …
pulmonary disease (COPD) receiving combination long-acting muscarinic antagonist/long …
The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population
D Liu, Q Song, Y Zeng, R Yi, Y Liu, X Li… - … Journal of Chronic …, 2023 - Taylor & Francis
Background We analyzed the clinical characteristics and outcomes in non-frequent
exacerbation patients with chronic obstructive pulmonary disease (COPD). Methods In this …
exacerbation patients with chronic obstructive pulmonary disease (COPD). Methods In this …
Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings
HJ Park, JU Lee, S Jeon, HS Lee, BY Kim, YJ Chae… - PloS one, 2024 - journals.plos.org
This study aimed to define real-world prescription patterns in Korea and compare the
effectiveness of chronic obstructive pulmonary disease (COPD) medications. We used …
effectiveness of chronic obstructive pulmonary disease (COPD) medications. We used …
Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
DMG Halpin, M Kerkhof, JB Soriano, H Mikkelsen… - Respiratory …, 2016 - Springer
Background Management guidelines of chronic obstructive pulmonary disease (COPD) are
mainly based on results of randomised controlled trials (RCTs), but some authors have …
mainly based on results of randomised controlled trials (RCTs), but some authors have …
Stepwise management of COPD: What is next after bronchodilation?
M Miravitlles, K Matsunaga… - Therapeutic Advances in …, 2023 - journals.sagepub.com
Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …
EVELUTÒ: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA …
RBMDM Mattiucci, GRESS Eckhardt… - Adv Ther, 2023 - openscience.ub.uni-mainz.de
Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no
longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) …
longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) …
Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
MLK Han, R Ray, J Foo, C Morel, B Hahn - NPJ Primary Care …, 2018 - nature.com
Dual bronchodilator maintenance therapy may benefit patients with moderate-to-severe
chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist …
chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist …
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled …
JC Samp, MJ Joo, GT Schumock… - Annals of …, 2017 - journals.sagepub.com
Background: The recent approval of several fixed-dose combination long-acting β2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA …
R Buhl, M Dreher, M Mattiucci-Guehlke… - Advances in …, 2023 - Springer
Abstract Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …
Fixed-dose combinations of long-acting bronchodilators for the management of COPD: global and asian perspectives
CK Rhee, H Yoshisue, R Lad - Advances in Therapy, 2019 - Springer
Maintenance bronchodilator therapy with long-acting β-agonists (LABAs) and long-acting
muscarinic antagonists (LAMAs) is the cornerstone treatment for patients with stable chronic …
muscarinic antagonists (LAMAs) is the cornerstone treatment for patients with stable chronic …